| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1955) |
| Entry Type: | Small molecule |
| Molecule Category: | Salt |
| UNII: | 4B3SC438HI |
| Parent Compound: | METHYLPHENIDATE |
| InChI Key | JUMYIBMBTDDLNG-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C14H20ClNO2 |
| Molecular Weight | 269.77 |
| AlogP | 2.09 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 38.33 |
| Molecular species | BASE |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 17.0 |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC06 neurotransmitter transporter family
|
- | 20-122 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Depressive Disorder | 3 | D003866 | ClinicalTrials |
| Fatigue | 3 | D005221 | ClinicalTrials |
| Tobacco Use Disorder | 3 | D014029 | ClinicalTrials |
| Sleep Wake Disorders | 2 | D012893 | ClinicalTrials |
| Neoplasms | 2 | D009369 | ClinicalTrials |
| Conduct Disorder | 1 | D019955 | ClinicalTrials |
| Multiple Sclerosis, Chronic Progressive | 1 | D020528 | ClinicalTrials |
| Multiple Sclerosis, Relapsing-Remitting | 1 | D020529 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEBI | 31836 |
| ChEMBL | CHEMBL1722 |
| EPA CompTox | DTXSID8020886 |
| FDA SRS | 4B3SC438HI |
| KEGG | D07806 |
| SureChEMBL | SCHEMBL41067 |